M
Marta Baleva
Researcher at Sofia Medical University
Publications - 32
Citations - 3084
Marta Baleva is an academic researcher from Sofia Medical University. The author has contributed to research in topics: Antiphospholipid syndrome & Antibody. The author has an hindex of 8, co-authored 31 publications receiving 2756 citations.
Papers
More filters
Journal ArticleDOI
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
Ricard Cervera,J.C. Piette,Josep Font,Munther A. Khamashta,Yehuda Shoenfeld,María Teresa Camps,Søren Jacobsen,Gabriella Lakos,Angela Tincani,Irene Kontopoulou-Griva,Mauro Galeazzi,Pier Luigi Meroni,Ronald H. W. M. Derksen,Philip G. de Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,Frédéric Houssiau,Jean-Christophe Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,Marie Claire Boffa,Graham R. V. Hughes,Miguel Ingelmo +27 more
TL;DR: An association with SLE, the patient's sex, and the patient’s age at disease onset can modify the disease expression and define specific subsets of APS.
Journal ArticleDOI
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
Ricard Cervera,Munther A. Khamashta,Y Shoenfeld,M. T. Camps,Søren Jacobsen,Emese Kiss,Margit Zeher,Angela Tincani,I. Kontopoulou-Griva,Mauro Galeazzi,Francesca Bellisai,Pier Luigi Meroni,R. H. W. M. Derksen,P. G. De Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,Frédéric Houssiau,Jean-Christophe Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,J.C. Piette,Gerard Espinosa,Silvia Bucciarelli,C. N. Pisoni,Maria Laura Bertolaccini,M. C. Boffa,G. R. V. Hughes +31 more
TL;DR: Patients with APS still develop significant morbidity and mortality despite current treatment, and it is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.
Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
Ricard Cervera,Ma. Khamashta,Y Shoenfeld,Mt Camps,S Jacobsen,E. Kiss,Mm Zeher,Angela Tincani,I. Kontopoulou Griva,Mauro Galeazzi,Francesca Bellisai,Pl Meroni,Rh Derksen,Pg Groot,E. Gromnica Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,F. Houssiau,J-C Gris,Isabelle Quéré,E. Hachulla,Carlos Vasconcelos,B. Roch,A. Fernández Nebro,J-C Piette,Gerard Espinosa,Silvia Bucciarelli,Cn Pisoni,M L Bertolaccini,M C Boffa,G. R. V. Hughes +31 more
Abstract: Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid syndrome (APS) during a 5-year period and to determine clinical and immunological parameters with prognostic significance. Methods: The clinical and immunological features of a cohort of 1000 patients with APS from 13 European countries who had been followed up from 1999 to 2004 were analysed. Results: 200 (20%) patients developed APS-related manifestations during the 5-year study period. Recurrent thrombotic events appeared in 166 (16.6%) patients and the most common were strokes (2.4% of the total cohort), transient ischaemic attacks (2.3%), deep vein thromboses (2.1%) and pulmonary embolism (2.1%). When the thrombotic events occurred, 90 patients were receiving oral anticoagulants and 49 were using aspirin. 31/420 (7.4%) patients receiving oral anticoagulants presented with haemorrhage. 3/121 (2.5%) women with only obstetric APS manifestations at the start of the study developed a new thrombotic event. A total of 77 women (9.4% of the female patients) had one or more pregnancies and 63 (81.8% of pregnant patients) had one or more live births. The most common fetal complications were early pregnancy loss (17.1% of pregnancies) and premature birth (35% of live births). 53 (5.3% of the total cohort) patients died. The most common causes of death were bacterial infection (21% of deaths), myocardial infarction (19%) and stroke (13%). No clinical or immunological predictor of thrombotic events, pregnancy morbidity or mortality was detected. Conclusion: Patients with APS still develop significant morbidity and mortality despite current treatment (oral anticoagulants or antiaggregants, or both).
Journal ArticleDOI
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period
Ricard Cervera,Munther A. Khamashta,Y Shoenfeld,M. T. Camps,S Jacobsen,E. Kiss,Margit Zeher,Angela Tincani,I. Kontopoulou-Griva,Mauro Galeazzi,Francesca Bellisai,Pl Meroni,R. H. W. M. Derksen,de Peter Groot,Erika Gromnica-Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,F. Houssiau,J-C Gris,Isabelle Quéré,Eric Hachulla,Carlos Vasconcelos,B. Roch,Antonio Fernández-Nebro,J-C Piette,Gerard Espinosa,Silvia Bucciarelli,Cecilia N. Pisoni,Maria Laura Bertolaccini,M C Boffa,G. R. V. Hughes +31 more
TL;DR: Patients with APS still develop significant morbidity and mortality despite current treatment (oral anticoagulants or antiaggregants, or both), according to this 5-year study.
Journal ArticleDOI
An antibody-based construct carrying DNA-mimotope and targeting CR1(CD35) selectively suppresses human autoreactive B-lymphocytes
Elisaveta Voynova,Andrey Tchorbanov,József Prechl,Milena Nikolova,Marta Baleva,Anna Erdei,Anna Erdei,Tchavdar L. Vassilev +7 more
TL;DR: It is found that the DNA-like peptide chimera induced a dose-dependent decrease in the number of IgG anti-dsDNA antibody producing cells when PBMCs of lupus patients were cultured in its presence.